En

ABOUT HOOMYA

關于宏雅



深圳市賽百諾中加基因技術有限公司 ÷ 是(shì)由臨床藥理(lǐ)學家(jiā)、我國₹≤ ♥(guó)遺傳藥理(lǐ)學與藥物(wù)基因組學的(de)開(∑$γ↓kāi)拓者和(hé)奠基人(rén)、個(gè)體(tǐ)化☆♦&↓(huà)醫(yī)學的(de)倡導者和(hé)引領者周宏灏院士及其團₹Ω♦隊發起設立，緻力于個(gè)體(tǐ)化(hu•γ<à)醫(yī)學（精準醫(yī)學）檢測≤★"技(jì)術(shù)的(de)研究與産業(yè)化(huà)的δ™φ(de)高(gāo)科(kē)技(jì)公司。公司主要(yào)從(c♦₹♣óng)事(shì)個(gè)體(tǐ)化(huà)醫(yī)學‌↓↓檢測産品（含産品科(kē)研、CDMO、儀器(qì)與設'♦≈>備、試劑耗材及檢測服務）的(de)開(kāi)發、運營與市(shì)場(ε ♣chǎng)推廣，打造精準醫(yī)學時(←♠shí)代的(de)專業(yè)個(gèφ←♥ )體(tǐ)化(huà)醫(yī)學檢測運營服•Ω§₽務平台.

Hunan Hongya Gene Technology Co., Ltd.↑ ≤ was founded by acade¶≠≥mician Zhou Honghao, a cliniε cal pharmacologist, pioneer and founder✔γ₹₩ of pharmacogenetics and pharσαα↕macogenomics in my country, ♦✘and advocate and leade→Ω≤r of personalized medicine,β≥§ and his team. It is≥ ₽∏ a high-tech company de ♣dicated to the research anδ<d industrialization of persona∏☆∞σlized medicine (precision medici¶∏ne) testing technology. The ₩☆company is mainly engaged in the $§ development, operation a↕₽∑nd marketing of personali≠±zed medicine testing ∏&products (including product res$∞πearch, CDMO, instruments and equiα≈pment, reagents and consumables, a♠φ£nd testing services), cr¥∏eating a professional personaliz★≤ed medicine testing operation se∑&↑±rvice platform in the era  ®of precision medicin÷λ←e.





公司聯合以湘雅醫(yī)學檢驗所為(wèi)主體(tǐ)的(♥≈γde)國(guó)內(nèi)外(wài)多(duō)家(jiā)÷β個(gè)體(tǐ)化(huà)醫(yī)學（精準醫(yī)學)專業(yè) '≈₩研究機(jī)構，引進頂尖學者、 美(m©♣ěi)國(guó)墨菲特癌症中心醫(yī)學主任霍華德 · L · 麥克勞德為(wèi)代表的(de)專家(jiā)技(jì)術(shù)團隊，整γ£合國(guó)內(nèi)外(wài)先進的(de≈☆×)個(gè)體(tǐ)化(huà)醫(yī)學檢測技(jì)術(shù)平台↔ λ， 以研發帶動生(shēng)産和(hé)銷售，依托具有(yǒ₽εu)先進性的(de)分(fēn)子(zǐ)診斷核心技(jì)術(shù)，在體©‌β≥(tǐ)外(wài)診斷，尤其是(shì)高ββ(gāo)端的(de)分(fēn)子(zǐ)診斷領域形成了(l₹φe) 一(yī)系列具有(y&↑ǒu)自(zì)主知(zhī)識産權的(de)産׶品。
    The company&≈ has joined forces with a numbα₽ αer of Personalized medicin↔✘≈‌e (precision medicine) p§λrofessional research institutes at •≥∑home and abroad, mainly based λ£on the Xiangya medical laboratory, howa$σrd L. McCloud, medical d<α<irector of the Murphy Cancer Ce<‌nter in the United States a"✔÷nd a leading scholar, was€&★ brought in to represent tλ 'he expert and technical team &δ★"to integrate advanced Per&§×sonalized medicine detecti∏•↑on technology platforms at home and a≠♦←≠broad, a series of products with φ‍independent intellec₹&×±tual property rights have b ©∏∞een developed in the f®¶ield of in vitro diag&★>γnosis, especially in high-end molecu×→lar diagnosis.

公司目前主營業(yè)務包括各類應用(yò& ♣ng)于無創産前篩查、疾病預測、疾病早期篩查、疾病早期分(fēn)子(zǐ)>‌>診斷與分(fēn) 子(zǐ)分(fēn)型、疾病個(gè)體(t&♥≤£ǐ)化(huà)用(yòng)藥指導、疾病$↓預後監測的(de)分(fēn)子(zǐ)檢測産品，×±♣>已形成覆蓋全國(guó)的(de)營銷網絡，成為(wèi)個(gè)體(tǐ‌™)化(huà) 醫(yī)學（精φ§¶準醫(yī)學）專業(yè)服務領域的(de)優勢品牌企業φ→(yè)。
    At prπ®esent, the company's &♠main business includes variousγ § applications in non-invasive prenatal $>screening, disease prediction, ★♦disease early screening, di¶♠₽Ωsease early molecular diagnosis and c"¶ ±lassification, the molecular dete"'ction products of sub-typi☆>♥ng, disease individualized medicat₩☆±Ωion guidance and disea₽↑∞αse prognosis monitoring have for×↓med a nationwide market•™™ing network and become indivi≈δdualized, medical (precision ♥ α medicine) professional serv&↓πδices in the field of♦ε♥↑ dominant brand enterprises

技(jì)術(shù)團隊Technical Team

公司聯合以湘雅醫(yī)學檢驗所為←±(wèi)主體(tǐ)的(de)國(guó)內γ★Ω (nèi)外(wài)多(duō)家(jiā)個(gè)體(tǐ)化¶♥>§(huà)醫(yī)學（精準醫(yī)學）專業(yè)研究機(j₽•φ→ī)構，引進以 頂尖學者、美(měi)國(g✘¶↓uó)墨菲特癌症中心醫(yī)學主任霍華德 · L · 麥克勞德d為(wèi)代表的(de)專家(jiā)技(↕π<₩jì)術(shù)團隊，整合 國(guó)內(nèi)外(π≥≈wài)先進的(de)個(gè)體(tǐ)化(huà)醫(yī)¶₩©✔學檢測技(jì)術(shù)平台，以研發帶動生(shēng)産和(hé)銷♣↑售，依托具有(yǒu)先進性的(de)分(fēn)子(®≤✘×zǐ)診斷核心技(jì)術(shù)， 在體(≥&"∞tǐ)外(wài)診斷，尤其是(shì)高(gāo)端的(de₽<©™)分(fēn)子(zǐ)診斷領域形成了(le)一(yī)系列具επ有(yǒu)自(zì)主知(zhī)識産權的(≥✘×'de)産品。
The company has team→ ed up with a number of Personalize★∏‌§d medicine (precision medicine) profess₩‍ional research institutes at h©₩÷ome and abroad, mainly based on the Xiaεβngya medical laboratory, howaΩ∞γ rd L. McCloud D, medical director of th♦÷₩≈e Murphy Cancer Center and a leadi€σ✘ng scholar, is the representatλ♦←ive of the expert and technical team, w≥↓×hich integrates the advanced♦©≈ Personalized medicine de¶≈✘tection technology platfo£€rm at home and abroad,π&εσ in vitro diagnosis,∏∑≠← especially in high-end molecular diagnΩε≠<osis field, has forme≥≈♦£d a series of products with independe®‍nt intellectual property rights, rel↑€©÷ying on advanced molecular diagnosis¶£δ core technology.

主營業(yè)務Business

公司目前主營業(yè)務包括各類應用(yòng)于無創産前篩查、疾病→★​預測、疾病早期篩查、疾病早期分(fēn)子(zǐ)診斷與分(fēn)子(γ₩zǐ) 分(fēn)型、疾病個(g→λè)體(tǐ)化(huà)用(yòng)藥指導、疾病預後監測的(±®≤αde)分(fēn)子(zǐ)檢測産品，業(yè)務版圖已遍布湖(hú↓♠§≤)南(nán)、湖(hú)北(běi)、江蘇、浙  ←®​ 江、安徽、上(shàng)海(hǎi)、北(bΩ←ěi)京、天津、河(hé)南(nán)、河(hé)北(běi)♦♦​♥、山(shān)東(dōng)、山(shān₩​÷)西(xī)、陝西(xī)、遼甯、廣東(dōng)、廣西(xī)、↑γ雲南(nán)、 貴州等地(dì)區®α(qū)。
At present, the company's≠₹γ main business includes various applica™‌tions in non-invasive prenatal screenin$♠>±g, disease prediction, disease ea≤×rly screening, disease early molecu™∞✘>lar diagnosis and molecular, molecul∏Ωφ<ar testing products for©¥' typing, individualized m $✘edication guidance, and disease prognos₽÷is monitoring, the busi¶ "¶ness scope has spread over Hunan, ♠♠™Hubei, Jiangsu, Zhejiang, Anhui, Shang¥✘​hai, Beijing, Tianjin, Henan,×♣ Hebei, Shandong, Shanxi, ShaanxΩ↕¥₽i, Liaoning, Guangdong, Guang™✔xi, Yunnan, Guizhou and other regions™±✔®.

行(xíng)業(yè)領域Industry sector

個(gè)體(tǐ)化(huà)醫(yī)學Personalized Medicine&nbs↓¶ p;

個(gè)體(tǐ)化(huà)醫(yī)學是(shì)2£"1世紀醫(yī)學發展的(de)必然趨勢。随著(zhe)λ÷σ×人(rén)類基因組計(jì)劃的(de)完成和(hé)後基因組學的(deΩ↑↓)深入研究， 越來(lái)越多(duō)的'' (de)緻病基因被定位，更多(duō)疾病發生(shēng)的(de)遺÷ε傳學基礎得(de)以闡明(míng)，與人(rén)類生(shēng≠ε)理(lǐ)、病理(lǐ)以及藥物(wù)效應 和("↕hé)毒副反應相(xiàng)關的(de)基因特征不(bùδ )斷被揭示，促使醫(yī)學模式由經典的(de)基于規律總結的(de)“标準׶化(huà)醫(yī)學”，向基 ←₽  于個(gè)體(tǐ)基因差異進行(x¶<φíng)的(de)“量體(tǐ)裁衣”式的(de)“個(gè)體(tǐ)化(h'♥‌uà)醫(yī)學”轉變。個(gè)體(tǐ)化(huà)∏$‌ 醫(yī)學是(shì)根據個(gè)體α₩ &(tǐ)的(de)基因信息對(duì)疾病 進行(₽∞÷→xíng)診斷、治療和(hé)風(fēng)險評估，使疾病的(de)診治更為¶∑(wèi)精确、高(gāo)效，顯著提升醫↔←$(yī)療質量。個(gè)體(tǐ)化(huà)醫(yī)學目前發 ¶÷→≈ 展最為(wèi)成熟的(de)領域是(shì)個(gè)體(t×$ǐ)化(huà)用(yòng)藥，即以每個(gè)患者的(de)基因信♠'息為(wèi)基礎決定個(gè)人(rén)的(de)藥物(wù)治療方&>>✔案，從(cóng)基因 組成或表達的‌≈♥(de)差異來(lái)預測疾病的(de)治療™☆γ>效果或毒副作(zuò)用(yòng)，對(duì)每個(gè)患★‍♦∞者選擇最适宜的(de)藥物(wù)療法進行(xíng)治療。 ≈α→個(gè)體(tǐ)化(huà)醫(yī)學彌補了(le)循證醫(yī)學的(α÷de)缺點，其治療更有(yǒu)針對(duì)性，可(kě)以按照(zhào)€↕個(gè)體(tǐ)對(duì)某種特定↑β&疾病易感性的(de)不(bù)同 ↓≈× 或對(duì)某種特定治療反應性的(de)不(bù)同，把人(¥β‍®rén)群分(fēn)為(wèi)不(bù)同的(de)亞πφ群，進而對(duì)患者進行(xíng)有(yǒu)效÷∞地(dì)預防或治療性幹預， 節↓"λ≤約醫(yī)療費(fèi)用(yòng)和(hπ ↕∞é)避免毒副反應Personalized✘¶÷✘ medicine is an inevitable tπ☆rend in the development o♣←f medicine in the 21​≠€♣st century.With the ∑¥completion of the human genomΩ♥‍e project and in-depth research on pos©>β©t-genomics, more and more dis↓₹ease-causing genes have been ¥γ located, and the genetic ba® ≈sis of more diseases has€★β been elucidated, which is rel₽∞↔&ated to human physioφ✘♠logy, pathology, drug e ≈ffects and toxic side effects.→®Ω€ Gene characteristics are constan€♠'tly being revealed, prompti÷'±↓ng the medical model to ¶ change from the clas♥£×sic "standardized medicΩ‌ ine" based on rule summa↕♥₹✘ries to "tailor-made" "i₹φndividualized medicine" based on←← individual genetic differences.♦ε×Personalized medicine is ✘<¥÷the diagnosis, treatmentγ₽• and risk assessment of<γ✔ diseases based on individual≈↕∞₽ genetic information, ₹∞♦♥making the diagnosis and tr©•γ₩eatment of diseases €φmore accurate and efficien§ ≈t, and significantly improving t↓®he quality of medical⧣≠ care.The most matureΩΩ♣↓ field of personalized medicine is ‍ &personalized medicine, whiשch determines indivi∞↓↑dual drug treatment plans based on each‌☆≠ patient'。

個(gè)體(tǐ)化(huà)醫(yī)學檢測Personalized Medicine

通(tōng)過利用(yòng)專業(yè)檢測儀器(qì)平台和(↓∏hé)配套的(de)試劑、耗材，檢測與疾病的(de)發生(shēng↓≈¶£)和(hé)用(yòng)藥相(xiàng)關基因的(≥<de)結構改變、表達 和(hé)代謝(xiè)變化(huà)≠€  等，進一(yī)步使用(yòng)數(s₹•hù)據庫、分(fēn)析模型、軟件(jiàn)等工(gō≈≥←♠ng)具對(duì)檢測結果進行(xíng)專業(yè☆£)分(fēn)析并對(duì)分(fēn)析結果進行(xín∏±g)專業(yè) 咨詢（針對(duì)受檢者及其λ←醫(yī)生(shēng)），對(duì)疾病進行(xíng)個(gè)性¶÷化(huà)的(de)預測、診斷、治療決策和↕‌׶(hé)檢測的(de)臨床檢測服務。